Announcements Trials
Browse Landscape

Phase

Phase 3 12Phase NA 7Phase 2 5Phase 1 3Phase EARLY_PHASE1 1Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Other solid neoplasm 1

Conditions

Prostatic Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Interventional × Selenium × Clear all
NCT01497431 2014-11-26

Se-Methyl-Seleno-L-Cysteine or Selenomethionine in Preventing Prostate Cancer in Healthy Participants

National Cancer Institute (NCI)

Phase 1 Completed
66 enrolled
Genitourinary

Prostatic Neoplasms

NCT00112892 2014-01-13

Irinotecan and Selenium in Treating Patients With Advanced Solid Tumors

Roswell Park Cancer Institute

Phase 1 Completed
36 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

NCT00217516 2012-02-09

Selenium in Treating Patients Who Are Undergoing Brachytherapy for Stage I or Stage II Prostate Cancer

Roswell Park Cancer Institute

Phase 1 Completed
18 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡